medscape.com
Real-World Data Show Efficacy of Risankizumab in Refractory Crohn's
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after failure of other biologics.
Adults with Crohn's disease, especially those who have tried multiple biologics; clinicians managing refractory IBD; researchers studying biologic sequencing.
What To Know
Nearly 60% of adults with refractory Crohn's disease in a large Spanish registry study achieved steroid-free clinical remission after starting risankizumab; remission rates were 56.4% at 8–12 weeks and 61.2% at last follow-up. Patients previously exposed to three or more advanced biologics had lower odds of remission than those exposed to two or fewer.
Adverse events were reported in 7.9% of patients and treatment discontinuation for adverse events occurred in 1.4% of the cohort. This was an observational analysis of 857 adults from the ENEIDA registry treated with an IV induction (600 mg at 0, 4, 8 weeks) followed by SC maintenance (360 mg every 8 weeks).
The main outcome was steroid-free clinical remission measured by the Harvey-Bradshaw Index (HBI). Endoscopic data were limited and the nonrandomized design means we cannot conclude causality.
If you or someone you care for is considering risankizumab, this real-world data suggest it can be effective in heavily pretreated patients, but prior multiple biologic exposures and older age were associated with lower remission odds.
Discuss with your clinician how prior treatment history and monitoring (including objective inflammation assessment) apply to your situation.
This was an observational registry study (nonrandomized) using clinical indices (HBI) for outcomes; endoscopic confirmation was limited. Registry funding and author relationships with industry were disclosed.
